Has Frances Falls received payments from drug or device companies?

Yes. Drug and device makers reported $7,969 in general payments to Frances Falls across 371 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Frances Falls did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Frances Falls come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Frances Falls

Family · Tuscaloosa, ALNPI 1881226348

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 371 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AstraZeneca at 24.9% of the total. 2025 is the largest year on record at $2,726, more than ten times the $158 reported in 2021. Among family clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,969in general payments, 2019–2025

Across 371 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$2K
GSK$1K
Regeneron Healthcare Solutions, Inc.$964
Sanofi$840
Takeda Pharmaceuticals U.S.A., Inc.$770
Amgen$308
plus $2K from 19 others

What the payments were for

Food & beverage$7,969100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	90	$1,983
GSK	82	$1,466
Regeneron Healthcare Solutions, Inc.	32	$964
Sanofi	29	$840
Takeda Pharmaceuticals U.S.A., Inc.	38	$770
Amgen	17	$308
Optinose US, Inc.	17	$244
Pfizer	10	$216
Novartis	7	$173
Grifols USA, LLC	7	$134
Biohaven Pharmaceuticals, Inc.	1	$123
Kaleo, Inc.	6	$107
Boehringer Ingelheim	7	$96
Genentech USA, Inc.	4	$87
Teva Pharmaceuticals USA, Inc.	5	$83
Hikma Pharmaceuticals USA	4	$73
ARS Pharmaceuticals Operations, Inc.	3	$69
Galderma Laboratories, L.p.	3	$48
Blueprint Medicines Corporation	2	$46
Merck	2	$32
Sanofi Pasteur Inc.	1	$30
Ionis Pharmaceuticals, Inc.	1	$21
Kedrion Biopharma, Inc.	1	$21
Dermavant Sciences, Inc.	1	$18
Paratek Pharmaceuticals, Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,969 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	34	$20,983
Fluticasone Propionate	14	$194
Montelukast Sodium	22	$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
GSKTrelegy Ellipta	$1,466	$20,98334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.

Other family in Tuscaloosa

Justin SimpsonTuscaloosa$43K
Ashley StinesTuscaloosa$29K
Lauren KyzarTuscaloosa$17K
Dee GuyTuscaloosa$14K
Haley TippsTuscaloosa$14K
Jeremy KelleyTuscaloosa$13K
Leigh Ann ChildressHuntsville$240K
Molly ReevesAuburn$158K
Christina CanteyHuntsville$118K
Leigh LunaMontgomery$69K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →